
- BioPharm International-11-15-2017
- Volume 2017 eBook
- Issue 3
Moving to Closed Systems for Aseptic Processing
Alternatives to time-consuming, error-prone operations promise to reduce vaccine manufacturing costs and improve facility flexibility.
As the authors write, true sterile manufacturing remains an impossible ideal. In the real world, even the slightest contact with operators can contaminate product. While aseptic processing has brought the industry closer to its goals, closed aseptic processing takes progress much further, by using automaton and isolators to prevent contamination. This article examines general trends but focuses on a technology that has been developed by Medinstill, that significantly reduces the risk of contamination and allows unclassified rooms to be used to process materials, instead of costly cleanrooms.
Download
eBook.
Article Details
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 31–38
Citation
When referring to this article, please cite it as J. Agalloco and L. Mestrandrea, " Moving to Closed Systems for Aseptic Processing," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Articles in this issue
almost 8 years ago
Designing and Operating Flexible, High-Containment Vaccine Manufacturingalmost 8 years ago
Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseasesalmost 8 years ago
Cold Chain: Delivering Vaccines to Patientsalmost 8 years ago
Using Human Challenge Trials to Develop Flu Vaccinesalmost 8 years ago
Making Vaccines Accessiblealmost 8 years ago
Accelerating Vaccine Development and ManufacturingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.